683 Capital Management’s Abeona Therapeutics ABEO Stock Holding History

683 Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-770,000	Closed	-$3.45M	–	154
2026 Q1	$3.45M	Hold	770,000	–	–	0.18%	88
2025 Q4	$4.06M	Hold	770,000	–	–	0.18%	93
2025 Q3	$4.07M	Buy	770,000 +20,000	+3%	+$127K	0.21%	82
2025 Q2	$4.26M	Buy	750,000 +75,000	+11%	+$427K	0.28%	81
2025 Q1	$3.21M	Sell	675,000 -116,845	-15%	-$635K	0.22%	93
2024 Q4	$4.41M	Buy	791,845 +116,845	+17%	+$719K	0.27%	69
2024 Q3	$4.27M	Buy	675,000 +75,000	+13%	+$392K	0.32%	66
2024 Q2	$2.54M	Buy	+600,000	New	+$3.06M	0.19%	84

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

683 Capital Management's ABEO Position: Q2 2026 in Review

683 Capital Management sold out of Abeona Therapeutics (ABEO) in Q2 2026, closing a stake of 770,000 shares — an estimated $3.45M sold.

683 Capital Management first reported a position in ABEO in Q2 2024 and held it in 8 quarters. The position peaked at $4.41M in Q4 2024. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

683 Capital Management reported no remaining Abeona Therapeutics position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 770,000 Abeona Therapeutics shares in Q2 2026, an estimated $3.45M.
683 Capital Management first reported a position in Abeona Therapeutics in Q2 2024 and held it in 8 quarters.
683 Capital Management's Abeona Therapeutics position peaked at $4.41M in Q4 2024.
127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.